1Saroj VR.Recombinant human thrombopoietin:clinical experience and in vivo biology[J].Semi Hemat,1998; 13:3261 -3268.
2Li ZZ,Yang C,Xia YP,et al.Thrombocytopenia caused by the deve lopment of antibodies to thrombopoietin[J].Blood,2001; 98:3241 -3248.
3Russell LB,Elizabeth OF,Grean M,et al.Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle che motherapy supported by megakaryocyte growth and development factor[J].Blood,2002 ;99:2599-2602.
4Casadevall N,Nataf J,Viron B,et al.Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythro poietin[J].N Engl J Med,2002;346:469 -475.
3GeddisAE,LindenHM,KaushanskyK.Thrombopoietin: a pan-hematopoietic cytokine [J].Cytokine Growth Factor Rev,2002,13(1):61-73.DOI: 10.1016/S1359-6101(01)00030-2.
4ChalmersS,TarantinoMD.Romiplostim as a treatment for immune thrombocytopenia: a review [J].J Blood Med,2015,6:37-44.DOI: 10.2147/JBM.S47240.
5KuterDJ,BusselJB,LyonsRM,et al.Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial [J].Lancet,2008,371(9610):395-403.DOI: 10.1016/S0140-6736(08)60203-2.
6KuterDJ,RummelM,BocciaR,et al.Romiplostim or standard of care in patients with immune thrombocytopenia[J].N Engl J Med,2010,363(20):1889-1899.DOI: 10.1056/NEJMoa1002625.
7KantarjianH,FenauxP,SekeresMA,et al.Safety and efficacy of romiplostim in patients with lower-risk myelodysplastic syndrome and thromboeytopenia[J].J Clin Oncol,2010,28(3):437-444.DOI: 10.1200/JCO.2009.24.7999.
8Erickson-MillerCL,DelormeE,TianSS,et al.Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist [J].Stem Cells,2009,27(2):424-430.DOI: 10.1634/stemcells.2008-0366.
9BusselJB,ChengG,SalehMN,et al.Eltrombopag for the treatment of chronic idiopathic thmmbocytopenie purpura[J].N Engl J Med,2007,357(22):2237-2247.DOI: 10.1056/NEJMoa073275.
10SalehMN,BusselJB,ChengG,et al.Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the longterm, open-label EXTEND study[J].Blood,2013,121(3):537-545.DOI: 10.1182/blood-2012-04-425512.
